Skip to main content
SpringerLink
Log in

NICE says yes to afatinib for NSCLC

  • News item
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. NICE. NICE draft guidance recommends new treatment for lung cancer. Media Release : 14 Mar 2014. Available from: URL: http://www.nice.org.uk.

  2. National Institute for Clinical Excellence (NICE). NICE proposes to recommend another treatment for multiple myeloma. Media Release : 20 Mar 2014. Available from: URL: http://www.nice.org.uk.

  3. The National Institute for Health and Care Excellence. NICE: Better information needed on multiple myeloma drug. Media Release : 13 Mar 2014. Available from: URL: http://www.nice.org.uk.

  4. NICE. NICE unable to give the go ahead to new prostate cancer drug in preliminary recommendations. Media Release : 24 Mar 2014. Available from: URL: http://www.nice.org.uk.

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

NICE says yes to afatinib for NSCLC. PharmacoEcon Outcomes News 699, 10 (2014). https://doi.org/10.1007/s40274-014-1147-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-014-1147-x

Search

Navigation